Australians with schizophrenia die 25 years earlier than the general population, University of Sydney researchers reveal in today’s Medical Journal of Australia.
The physical health of people with schizophrenia needs serious and urgent national attention, according to the report’s authors, who say a lack of coordinated care between hospitals, community mental health services, GPs and other primary health care professionals is responsible for the gap in life expectancy.
“This is a preventable tragedy,” said the report’s senior author, psychiatrist, Professor Tim Lambert of the University of Sydney Collaborative Centre for Cardiometabolic Health in Psychosis (ccCHiP).
“People with schizophrenia and psychosis die early in life mainly from heart attacks, heart disease, and strokes due to untreated hypertension and high cholesterol, and high rates of obesity and smoking.
“There is no mystery about how to manage these diseases and risk factors. They should have their physical health checked annually by GPs and primary health care professionals and, where possible, reviewed in specialised multidisciplinary settings such as ccCHiP to formulate longer term interventions and preventative follow-up.”
There is no mystery about how to manage these diseases and risk factors.
The MJA report also says psychotropic agents, used in the treatment of schizophrenia and psychosis, can increase weight and promote dyslipidemia (abnormal blood fats) that elevate the risk of poor heart health.
The new research finds Clozapine, an antipsychotic drug used to treat the most severe forms of schizophrenia, is linked to a higher the risk of myocarditis and cardiomyopathy, heart conditions that can cause sudden cardiac death, though with appropriate medical care is among the safest of the antipsychotics with respect to premature death.
Patients starting clozapine therapy should be screened for myocarditis have ongoing monitoring for cardiomyopathy with echocardiography, say the authors, as part of the more general management of cardio-metabolic risk in this highly vulnerable population.
For the first time, details about Australians using over-the-counter reliever puffers have been revealed, indicating people may be placing themselves at risk by not getting a diagnosis and taking preventative medication.